World's Scariest Drug - Scopolamine

World's Scariest Drug
Read Here
and Here and Here

Scopolamine
Julia Bedell, Laci Click, Meredith Barr
Scopolamine.ppt

Indirect cholinergic agonists
Indirect cholinergic agonists.ppt

Cholinergic Agonism and Antagonism Module
MARCELO G. BONINI
Cholinergic Agonism and Antagonism.ppt

Psychoactive and Poisonous Plants
psychoactiveplants_spring11.ppt

Anesthesia for Trauma
Christopher DeSantis, MD
Anesthesia_for_Trauma_1_.ppt

Belladonna leaves
Belladonna.ppt

Muscarinic Antagonists
Neil M. Nathanson
Muscarinic Antagonists.ppt

Cholinergics & anticholinesterases
Cholinergics & anticholinesterases.ppt

Cholinergic System
Cholinergic System.ppt

Gastrointestinal Agents
Gastrointestinal Agents.ppt
200 free full text articles on Scopolamine

1. Phellodendron amurense and Its Major Alkaloid Compound, Berberine Ameliorates Scopolamine-Induced Neuronal Impairment and Memory Dysfunction in Rats.
2. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress.
3. Scopolamine administration modulates muscarinic, nicotinic and NMDA receptor systems.
4. Transdermal delivery of scopolamine by natural submicron injectors: in-vivo study in pig.
5. Protective role of Ashwagandha leaf extract and its component withanone on scopolamine-induced changes in the brain and brain-derived cells.
6. [Comparison in dissolution behavior of ethical and over-the counter scopolamine butylbromide].
7. In vivo investigation of the neuroprotective property of Convolvulus pluricaulis in scopolamine-induced cognitive impairments in Wistar rats.
8. Rehmannia glutinosa ameliorates scopolamine-induced learning and memory impairment in rats.
9. Prophylaxis of postoperative nausea and vomiting in adolescent patients: a review with emphasis on combination of fixed-dose ondansetron and transdermal scopolamine.
10. A novel spray-dried nanoparticles-in-microparticles system for formulating scopolamine hydrobromide into orally disintegrating tablets.
11. Bacopa monniera Attenuates Scopolamine-Induced Impairment of Spatial Memory in Mice.
12. Cognitive enhancing and antioxidant activity of ethyl acetate soluble fraction of the methanol extract of Hibiscus rosa sinensis in scopolamine-induced amnesia.
13. A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment.
14. The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs.
15. Efficacy study of Prunus amygdalus (almond) nuts in scopolamine-induced amnesia in rats.
16. Antiamnesic effect of stevioside in scopolamine-treated rats.
17. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
18. Management of drooling in disabled patients with scopolamine patches.
19. Cholinergic influence on memory stages: A study on scopolamine amnesic mice.
20. The effect of transdermal scopolamine plus intravenous dexamethasone for the prevention of postoperative nausea and vomiting in patients with epidural PCA after major orthopedic surgery.
21. Interactions between morphine, scopolamine and nicotine: schedule-controlled responding in rats.
22. Scopolamine treatment and muscarinic receptor subtype-3 gene ablation augment azoxymethane-induced murine liver injury.
23. Dose effects of triazolam and scopolamine on metamemory.
24. Vitamin C deficiency increases basal exploratory activity but decreases scopolamine-induced activity in APP/PSEN1 transgenic mice.
25. Gluco-obtusifolin and its aglycon, obtusifolin, attenuate scopolamine-induced memory impairment.
26. Ginsenoside Rh2 ameliorates scopolamine-induced learning deficit in mice.
27. Anticholinergic syndrome following an unintentional overdose of scopolamine.
28. Ascorbic acid attenuates scopolamine-induced spatial learning deficits in the water maze.
29. Scopolamine-induced migraine like headache.
30. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
31. Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity.
32. Mangiferin ameliorates scopolamine-induced learning deficits in mice.
33. Combined scopolamine and ethanol treatment results in a locomotor stimulant response suggestive of synergism that is not blocked by dopamine receptor antagonists.
34. Premarin improves memory, prevents scopolamine-induced amnesia and increases number of basal forebrain choline acetyltransferase positive cells in middle-aged surgically menopausal rats.
35. Intra-dorsal hippocampal microinjections of lithium and scopolamine induce a cross state-dependent learning in mice.
36. [Determination of hyoscyamine and scopolamine in serum and urine of humans by liquid chromatography with tandem mass spectrometry].
37. Scopolamine impairs auditory delayed matching-to-sample performance in monkeys.
38. Zeatin supplement improves scopolamine-induced memory impairment in mice.
39. Control of drooling using transdermal scopolamine skin patches. A case report.
40. Protective effects of Punica granatum seeds extract against aging and scopolamine induced cognitive impairments in mice.
41. 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine.
42. The seed extract of Cassia obtusifolia ameliorates learning and memory impairments induced by scopolamine or transient cerebral hypoperfusion in mice.
43. Effect of Polygala tenuifolia root extract on scopolamine-induced impairment of rat spatial cognition in an eight-arm radial maze task.
44. Scopolamine infused into perirhinal cortex improves object recognition memory by blocking the acquisition of interfering object information.
45. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery.
46. Formation of scopolamine from N-butyl-scopolammonium bromide in cigarettes.
47. Scopolamine prevents dreams during general anesthesia.
48. Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy.
49. Behavioral characterization of a transection of dorsal CA3 subcortical efferents: comparison with scopolamine and physostigmine infusions into dorsal CA3.
50. Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms.
51. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
52. Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
53. Paradoxical facilitation of object recognition memory after infusion of scopolamine into perirhinal cortex: implications for cholinergic system function.
54. Testing for atropine and scopolamine in hair by LC-MS-MS after Datura inoxia abuse.
55. Memory-enhancing effect of a supercritical carbon dioxide fluid extract of the needles of Abies koreana on scopolamine-induced amnesia in mice.
56. [Effects of midazolam on muscarinic receptor of brain in healthy and scopolamine-treated rats].
57. [Scopolamine poisoning ('burundanga'): loss of the ability to make decisions].
58. Acteoside of Callicarpa dichotoma attenuates scopolamine-induced memory impairments.
59. Scopolamine reduces persistent activity related to long-term encoding in the parahippocampal gyrus during delayed matching in humans.
60. Effect of a nutritive-tonic drink on scopolamine-induced memory impairment in mice.
61. Spasmolysis at CT colonography: butyl scopolamine versus glucagon.
62. A synthetic retinoid Am80 (tamibarotene) rescues the memory deficit caused by scopolamine in a passive avoidance paradigm.
63. The effects on place cells of local scopolamine dialysis are mimicked by a mixture of two specific muscarinic antagonists.
64. Determination of the effectiveness of components of the herbal medicine Toki-Shakuyaku-San and fractions of Angelica acutiloba in improving the scopolamine-induced impairment of rat's spatial cognition in eight-armed radial maze test.
65. Cholinergic modulation of visual attention and working memory: dissociable effects of basal forebrain 192-IgG-saporin lesions and intraprefrontal infusions of scopolamine.
66. No influence of scopolamine hydrobromide on odor detection performance of rats.
67. The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats.
68. Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat.
69. Potentiometric PVC membrane sensor for the determination of scopolamine in some pharmaceutical formulations.
70. Behavioural responsiveness to amphetamine or scopolamine following repeated exposure to chlorphenvinphos in rats.
71. Low dose transdermal scopolamine increases cardiac vagal tone in patients after acute myocardial infarction.
72. Scopolamine and the murder of King Hamlet.
73. Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study.
74. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review.
75. Effects of scopolamine and physostigmine on acquisition of morphine-treated rats in Morris water maze performance.
76. Excitotoxic median raphe lesions aggravate working memory storage performance deficits caused by scopolamine infusion into the dentate gyrus of the hippocampus in the inhibitory avoidance task in rats.
77. Reversal of scopolamine-induced spatial memory deficits in rats by TAK-147.
78. Attenuation of scopolamine-induced and age-associated memory impairments by the sigma and 5-hydroxytryptamine(1A) receptor agonist OPC-14523 (1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2[1H]-quinolinone monomethanesulfonate).
79. Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat.
80. Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy--a comparative study with butyl scopolamine bromide.
81. Effect of polyacetylenes on the neurite outgrowth of neuronal culture cells and scopolamine-induced memory impairment in mice.
82. [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo.
83. Huperzine A reverses scopolamine- and muscimol-induced memory deficits in chick.
84. Scopolamine enhances generalization between odor representations in rat olfactory cortex.
85. Facilitating effects of histamine on spatial memory deficit induced by scopolamine in rats.
86. The scopolamine-induced impairment of spatial cognition parallels the acetylcholine release in the ventral hippocampus in rats.
87. Scopolamine bioavailability in combined oral and transdermal delivery.
88. Effect of intracerebroventricular administration of soybean lecithin transphosphatidylated phosphatidylserine on scopolamine-induced amnesic mice.
89. Effects of microdialyzed oxotremorine, carbachol, epibatidine, and scopolamine on intraspinal release of acetylcholine in the rat.
90. Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT(1A) receptors in the dorsal raphe.
91. Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
92. Local infusion of scopolamine into intraparietal cortex slows covert orienting in rhesus monkeys.
93. Scopolamine and Pavlovian fear conditioning in rats: dose-effect analysis.
94. Intravenous scopolamine is potently self-administered in drug-naive mice.
95. Age-related effects of scopolamine on REM sleep regulation in normal control subjects: relationship to sleep abnormalities in depression.
96. American ginseng extract reduces scopolamine-induced amnesia in a spatial learning task.
97. S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine.
98. Attenuation of scopolamine-induced deficits in navigational memory performance in rats by bis(7)-tacrine, a novel dimeric AChE inhibitor.
99. Cerebral blood flow responses to somatosensory stimulation are unaffected by scopolamine in unanesthetized rat.
100. Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.
101. Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats.
102. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats.
103. Effect of long-term administration of berberine on scopolamine-induced amnesia in rats.
104. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
105. Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: a positron emission tomography study in unanesthetized monkeys.
106. NTP Toxicology and Carcinogenesis Studies of Scopolamine Hydrobromide Trihydrate (CAS No. 6533-68-2) in F344 Rats and B6C3F1 Mice (Gavage Studies).
107. Scopolamine patch can be confusing to the patient and anesthesiologist: a case report.
108. Physostigmine reversal of scopolamine-induced hypofrontality.
109. Double blind placebo controlled trial of short term transdermal scopolamine on heart rate variability in patients with chronic heart failure.
110. Scopolamine poisoning among heroin users--New York City, Newark, Philadelphia, and Baltimore, 1995 and 1996.
111. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure.
112. Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine.
113. Effects of scopolamine on human brain glucose consumption.
114. Tetramethylpyrazine improves spatial cognitive impairment induced by permanent occlusion of bilateral common carotid arteries or scopolamine in rats.
115. Effects of isovanihuperzine A on cholinesterase and scopolamine-induced memory impairment.
116. Intraseptal galanin potentiates scopolamine impairment of delayed nonmatching to sample.
117. Involvement of beta-adrenergic systems in the antagonizing effect of paeoniflorin on the scopolamine-induced deficit in radial maze performance in rats.
118. Involvement of alpha 1- but not alpha 2-adrenergic systems in the antagonizing effect of paeoniflorin on scopolamine-induced deficit in radial maze performance in rats.
119. Improving effects of FG-7080, a serotonin reuptake inhibitor, on scopolamine-induced performance deficits of memory tasks in rats.
120. Scopolamine impairs object exploration but not habituation in rats.
121. Protective effect of eurystatins A and B, new prolyl endopeptidase inhibitors, on scopolamine-induced amnesia in rats.
122. Circadian effects of scopolamine on memory, exploratory behavior, and muscarinic receptors in mouse brain.
123. Transdermal scopolamine as treatment of bradyarrhythmias.
124. Atypical response to scopolamine in a patient with type IV hereditary sensory and autonomic neuropathy.
125. In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography.
126. Acute complete heart block during anesthesia in a patient with severe coronary artery disease: effect of scopolamine versus ischemia of the AV node.
127. Scopolamine poisoning from homemade 'moon flower' wine.
128. Transdermal scopolamine and postoperative nausea and vomiting.
129. Scopolamine-induced alterations in predatory behaviour pattern in cats.
130. WEB 1881 FU ameliorates impairment of working memory induced by scopolamine and cerebral ischemia in the three-panel runway task.
131. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy.
132. Cross interaction between methamphetamine and scopolamine by means of ambulatory activity in mice.
133. Transdermal scopolamine decreases nausea and vomiting following cesarean section in patients receiving epidural morphine.
134. The role of body turn-brightness associations in the effect of scopolamine on response-to-change in the rat.
135. Scopolamine reduces frontal cortex perfusion.
136. Treatment of chronic symptomatic supraventricular bradyarrhythmias with transdermal scopolamine.
137. Effects of scopolamine on repeated acquisition of radial-arm maze performance by rats.
138. Premedication and high-dose fentanyl anesthesia for myocardial revascularization: a comparison of lorazepam versus morphine-scopolamine.
139. Cue distinctiveness and response-to-change in scopolamine injected or hippocampal rats.
140. Characteristics of effects of repeated scopolamine administration on ambulatory activity in mice and methamphetamine sensitivity in the scopolamine-experienced mice: comparison among 6 strains.
141. Transdermal scopolamine and gastric acid secretion.
142. Epoxidation in vivo of hyoscyamine to scopolamine does not involve a dehydration step.
143. [Effects of scopolamine plus atropine on experimental myocardial infarction in rabbits].
144. Effects of transdermal scopolamine, alone or in combination with cimetidine, on total 24 hour gastric acid secretion in patients with duodenal ulcer.
145. [Effects of syntropan, atropine and scopolamine on the uptake of GABA by homogenates of the rat cerebrum].
146. [Effects of anisodamine and scopolamine on pulmonary circulation in rabbits].
147. Psychosis due to transdermally administered scopolamine.
148. Effects of bifemelane hydrochloride (MCI-2016) on acetylcholine level reduced by scopolamine, hypoxia and ischemia in the rats and mongolian gerbils.
149. Scopolamine, morphine, and brain-stem auditory evoked potentials in awake monkeys.
150. Relationship between heterosynaptic reflex facilitation and acquisition of the nictitating membrane response in control and scopolamine-injected rabbits.
151. [Effect of scopolamine on action potential of myocardial cell of guinea pig].
152. Muscimol-scopolamine interactions in the rat brain: a study with 2-deoxy-D-[1-14C]glucose.
153. [Antagonism of 4-aminopyridine on the central nervous system depressant effects of scopolamine in rabbits].
154. Circadian variation in susceptibility to the ambulation-increasing effect of scopolamine in mice.
155. Development of tolerance to ambulation-increasing effect of scopolamine dependent on environmental factors in mice.
156. [Central antimuscarinic cholinergic effects of scopolamine and other cholinergic antagonists].
157. Effect of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI-2016) on the scopolamine-induced deficit of spontaneous alternation behavior in rats.
158. [Central effects of anisodamine, atropine, anisodine and scopolamine after intraventricular injection].
159. [Central inhibitory effect of scopolamine and its adrenergic antagonistic activity (author's transl)].
160. [Dualistic action of scopolamine on avoidance conditioned response in dogs (author's transl)].
161. Atrophine, scopolamine, and glycopyrrolate.
162. Effects of methamphetamine and scopolamine on variability of response location.
163. The involvement of catecholamine in scopolamine-induced locomotor activation and rotational behaviour in mice.
164. Cardiovascular effects of scopolamine during morphine-oxygen and morphine-nitrous oxide-oxygen anesthesia in man.
165. Amnesic actions of diazepam and scopolamine in man.
166. Paradoxical reaction to intravenous pentobarbital, meperidine and scopolamine.
167. Proceedings: Effects of atropine and scopolamine on the timing response in rats.
168. Failure of scopolamine, pilocarpine or phenoxybenzamine to influence the rate of oviduct secretion in the rabbit.
169. Respiratory pharmacology of mixtures of scopolamine with secobarbital and with fentanyl.
170. The effects of scopolamine on the airways of man.
171. Ocular manifestations of parenteral administration of scopolamine (hyoscine).
172. Development of behavioral compensation to the effects of scopolamine during fixed-interval reinforcement.
173. Effects of atropine and scopolamine on the cardiovascular system in man. 2. Secondary bradycardia after scopolamine.
174. Effects of atropine and scopolamine on the cardiovascular system in man.
175. The studies on the residual accommodation of Koreans. II. The residual accommodation under 0.5 percent scopolamine and 1 percent cyclogyl cycloplegia.
176. Atropine, scopolamine, and related compounds.
177. Effects of intravenous atropine and scopolamine during cyclopropanesuccinylcholine anesthesia.
178. A comparison of atropine, or scopolamine, plus pentobarbital, meperidine, or morphine as pediatric preanesthetic medication.
179. The action of atropine, benactyzine, and scopolamine upon fixed-interval and fixed-ratio behavior.
180. Effects of scopolamine on a multiple schedule.
181. Scopolamine-methadon-demerol treatment of emergency status asthmaticus.
182. Effect of atropine, scopolamine and meperidine on man.
183. Hypertrophic pyloric stenosis in infancy treated with methyl scopolamine nitrate.
184. The effect of atropine and scopolamine on the subsequent injection of epinephrine in thyrotoxic and euthyroid patients.
185. Continuous intravenous drip of meperidine and scopolamine for relief of pains of labor.
186. The inhibition of sweating in man by scopolamine.
187. The effects of large doses of barbiturates and morphine and scopolamine on respiratory minute volume exchange.
188. Edema of the uvula, a manifestation of scopolamine sensitivity.
189. Intravenous demerol-scopolamine amnesia during labor.
190. Pethidine and scopolamine in labour.
191. Different Effect of Scopolamine on Peroral and Subcutaneous Administration.
192. Hyoscine (scopolamine) amnesia in labour.
193. Morphine-Scopolamine Narco-Anaesthesia in Nasal Operations.
194. Pituitary Extract and Scopolamine-Morphine in Obstetrics.
195. The Use of Pituitary Extract and Scopolamine-Morphine in Obstetrics.
196. Will the use of scopolamine-morphine in labour help to improve the birth-rate?
197. Report of the committee appointed by the section of obstetrics and gynaecology to investigate the effects of scopolamine-morphine narcosis, "twilight sleep," in childbirth.
198. observations On Painless Childbirth: With Notes Of Fifty Consecutive Cases Treated By The Hyoscine (Scopolamine) And Morphine Method.
199. Notes on painless childbirth: (hyoscine (scopolamine) and morphine.).
200. Results of scopolamine-morphine treatment during labour in 150 consecutive cases.